The National Medical Products Administration released updated registration documents and submission material requirements for business entities in 2026. These updates are aimed at standardizing submission formats and improving registration efficiency for drug applicants.
Key highlights:
- Updates documentation requirements for registration submissions
- Standardizes submission formats for applicants
- Improves Regulatory review efficiency
- Impacts both domestic and overseas pharmaceutical applicants
This update is important for companies preparing product registrations in China.
Source
Select Mandate HA
Select Mandate Function